Immunicum continues cell therapy trials after positive kidne...

Sweden’s Immunicum has announced detailed results from its mid-stage trial of its oncology cell-based immunotherapy ilixadencel, which it says justify further clinical trials after it impro

Keytruda combo cleared as first-line kidney cancer treatment...

Immunicum shares fall despite “fantastic” kidney cancer data

Merck & Co to buy cancer biotech Peloton for $2.2bn

Merck & Co is to buy the privately-held biotech Peloton for up to $2.2 billion, adding further oncology drugs to its pipeline as it searches for successors to cancer blockbuster Keytrud

Merck/Pfizer up the pressure on BMS in first-line kidney can...

The FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney cancer, setting up a possible approval in June and piling more pressure on Bristol

Merck's Keytruda gets boost in kidney and head and neck canc...

Merck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Bristol-Myers Squibb, with positive results in kidney cancer, and the promise of an F